Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the...
UroToday.com - The treatment of lower urinary tract symptoms (LUTS) secondary to bladder outlet obstruction (BOO) makes up a significant amount of the workload of most urologists. The traditional approach of trans urethral resection of the prostate (TURP) has been the mainstay of surgery for...